DexCom (DXCM)
NASDAQ: DXCM · Medical Devices · San Diego, CA
Our rating: Positive
Call changed from Neutral to Positive at $82.29, moderate conviction, October 30, 2026.
Breaks if: The positive call is broken if revenue growth decelerates to below 8% year-over-year in two consecutive quarterly reports within the next twelve months — at that pace, the 39.4x P/E multiple becomes difficult to defend and the core thesis of a durable, growing franchise loses its foundation. Separately, a 25% drawdown from the current price of $82.29 within twelve months, absent any parallel deterioration in reported fundamentals, would instead signal a market overreaction and prompt a reassessment toward the upside rather than the downside.
Key figures
| Market value | $29.6B |
|---|---|
| Revenue, last 12 months | $5.1B |
| Net income, last 12 months | $991M |
| Free cash flow, last 12 months | $1.1B |
| Price to earnings | 29.9× |
| Free cash flow yield | 3.7% |
| Dividend yield | 0.0% |
| Operating margin | 24.0% |
| Return on equity | 37.7% |
| Beta to the S&P 500 | 0.78 |
| Volatility, annualized | 48.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.3B | 11.2% | $0.72 | $273M |
| June 30, 2026 | $1.3B | 13.1% | $0.64 | $185M |
| March 31, 2026 | $1.2B | 15.0% | $0.51 | $449M |
| December 31, 2025 | $1.3B | 13.1% | $0.67 | $192M |
| September 30, 2025 | $1.2B | 21.6% | $0.70 | $579M |
| June 30, 2025 | $1.2B | 15.2% | $0.45 | $209M |
| March 31, 2025 | $1.0B | 12.5% | $0.27 | $97M |
| December 31, 2024 | $1.1B | 7.6% | $0.38 | $177M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.42B: Claude 52%, Gemini 60%, Mistral 47%
- Diluted earnings per share are at least $0.67: Claude 55%, Gemini 85%, Mistral 55%
- Free cash flow for the quarter is at least $0.19B: Claude 58%, Gemini 35%, Mistral 60%
17 ledger entries and 37 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.